Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: The Business Research Company | PRODUCT CODE: 1210159

Cover Image

PUBLISHER: The Business Research Company | PRODUCT CODE: 1210159

Oncology Biosimilars Global Market Report 2023

Published: Pre-Order
PAGES: 250 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
PDF (Single User License)
USD 5000
PDF (Site License)
USD 7500
PDF (Enterprise License)
USD 10000

Add to Cart

Contact us about how to customize the report with add-on data.

“Oncology Biosimilars Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oncology biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oncology biosimilars ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The oncology biosimilars market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Drug Type: Monoclonal Antibody; Immunomodulators; Hematopoietic Agents; Granulocyte Colony-Stimulating Factor (G-CSF)

2) By Cancer Type: Breast Cancer; Colorectal Cancer; Blood Cancer; Neutropenia Cancer; Non-Small Cell Lung Cancer; Other Cancer Types

3) By Distribution Type: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy

Companies Mentioned: Biocoin; Celltrion Inc.; Dr. Reddy's Laboratories Ltd.; Intas Pharmaceuticals Ltd.; STADA Arzneimittel AG

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major players in the oncology biosimilars market are: Bitcoin, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD, Amgen, Hospira, F Hoffmann-La Roche, Baxter, Sanofi, Mylan, and F Hoffmann-La Roche.

The global oncology biosimilars market is expected to grow from $3.27 billion in 2021 to $4.19 billion in 2022 at a compound annual growth rate (CAGR) of 28.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, causing inflation across goods and services effecting many markets across the globe. The oncology biosimilars market is expected to reach $11.35 billion in 2026 at a CAGR of 28.3%.

The oncology biosimilars market consists of sales of ogivri, herzuma, ontruzant, and trazimera. Values in this market are: 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Oncology biosimilars refer to biologically similar drugs or medications that are physiologically comparable to biologic cancer treatments. Infection risk is increased by decreased white blood cell counts, which can be treated as a side effect of cancer therapy.

North America was the largest region in the oncology biosimilars market in 2022. Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the oncology biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main drug types of oncology biosimilars are monoclonal antibodies, immunomodulators, hematopoietic agents, and granulocyte colony-stimulating factor (G-CSF). Immunomodulators are a class of drugs that primarily target pathways involved in the treatment of multiple myeloma and a few other cancers. The types of cancer treated include breast cancer, colorectal cancer, blood cancer, neutropenia cancer, and non-small cell lung cancer, and the various distribution channel involved are hospital pharmacies, retail pharmacies, and online pharmacies.

The expiration of the patent of biologics used for the treatment of cancer is driving the production of new oncology biosimilars. Biologics can be patented for a limited period and the expiration of patents for biologics allows the development of new biosimilars. Biologics are targeted drugs synthesized from living organisms that induce the immune system to attack cancer cells. Biosimilars are similar to biologics but are not identical and offer the same effectiveness as biologics at a reduced cost. According to the Center for Biosimilars, patents on nearly 20 oncology biologics will expire by 2023, leading to the development of new biosimilars in cancer care. The increased number of patent expiry is expected to boost the demand for the production of new oncology biosimilars, thus, driving the market growth for oncology biosimilars.

The lack of awareness of biosimilars among primary care physicians (PCPs) and specialists limits the growth of the oncology biosimilars market. Biosimilars are manufactured from cell lines and offer the same effectiveness as biologics. However, a lack of detailed awareness of the biosimilars amongst the prescribers reduces the prescriptions of biosimilars affecting the biosimilar market. For instance, as reported by the Health Research Institute of PricewaterhouseCoopers, out of 442 clinicians surveyed 55% of clinicians were unfamiliar with biosimilars and 35% were reluctant to prescribe them due to concerns including the safety of the follow-on biologic. Thus, the lack of awareness about biosimilars among primary care physicians (PCPs) and specialists restricts the growth of the oncology biosimilars market.

The pharmaceutical companies are increasingly investing in research and development to produce new oncology biosimilars. The companies are exploiting the growth potential of the rising biosimilar market by investing in their research and development (R&D) processes to support the research and production process of new biosimilars. For instance, in February 2021, Coherus and Junshi Biosciences announced a collaboration in which Coherus would in-license toripalimab, an anti-PD-1 antibody in the US and Canada. Coherus plan to build a leading immuno-oncology franchise using cash from its commercial biosimilar business. Also, in 2019, Biocon, India's largest biotechnology company invested to acquire some assets of Pfizer Healthcare to set up an R&D facility to boost biosimilar development.

The countries covered in the oncology biosimilars market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The market value is defined as the revenues that enterprises gain from goods and/or services sold within the specified market and geography through sales, grants, or donations in terms of currency (in USD ($) unless otherwise specified).

The revenues for a specified geography are consumption values - that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products.

The oncology biosimilars market research report is one of a series of new reports from The Business Research Company that provides oncology biosimilars market statistics, including oncology biosimilars industry global market size, regional shares, competitors with an oncology biosimilars market share, detailed oncology biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the oncology biosimilars industry. This oncology biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Product Code: r2012

Table of Contents

1. Executive Summary

2. Oncology Biosimilars Market Characteristics

3. Oncology Biosimilars Market Trends And Strategies

4. Oncology Biosimilars Market - Macro Economic Scenario

4.1 COVID-19 Impact On Oncology Biosimilars Market

4.2 Ukraine-Russia War Impact On Oncology Biosimilars Market

4.3 Impact Of High Inflation On Oncology Biosimilars Market

5. Oncology Biosimilars Market Size And Growth

  • 5.1. Global Oncology Biosimilars Historic Market, 2017-2022, $ Billion
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints On The Market
  • 5.2. Global Oncology Biosimilars Forecast Market, 2022-2027F, 2032F, $ Billion
    • 5.2.1. Drivers Of The Market
    • 5.2.2. Restraints On the Market

6. Oncology Biosimilars Market Segmentation

  • 6.1. Global Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Monoclonal Antibody
  • Immunomodulators
  • Hematopoietic Agents
  • Granulocyte Colony-Stimulating Factor (G-CSF)
  • 6.2. Global Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Breast Cancer
  • Colorectal Cancer
  • Blood Cancer
  • Neutropenia Cancer
  • Non-Small Cell Lung Cancer
  • Other Cancer Types
  • 6.3. Global Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

7. Oncology Biosimilars Market Regional And Country Analysis

  • 7.1. Global Oncology Biosimilars Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 7.2. Global Oncology Biosimilars Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

8. Asia-Pacific Oncology Biosimilars Market

  • 8.1. Asia-Pacific Oncology Biosimilars Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

9. China Oncology Biosimilars Market

  • 9.1. China Oncology Biosimilars Market Overview
  • 9.2. China Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

10. India Oncology Biosimilars Market

  • 10.1. India Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

11. Japan Oncology Biosimilars Market

  • 11.1. Japan Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

12. Australia Oncology Biosimilars Market

  • 12.1. Australia Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

13. Indonesia Oncology Biosimilars Market

  • 13.1. Indonesia Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

14. South Korea Oncology Biosimilars Market

  • 14.1. South Korea Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

15. Western Europe Oncology Biosimilars Market

  • 15.1. Western Europe Oncology Biosimilars Market Overview
  • 15.2. Western Europe Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

16. UK Oncology Biosimilars Market

  • 16.1. UK Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

17. Germany Oncology Biosimilars Market

  • 17.1. Germany Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

18. France Oncology Biosimilars Market

  • 18.1. France Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

19. Eastern Europe Oncology Biosimilars Market

  • 19.1. Eastern Europe Oncology Biosimilars Market Overview
  • 19.2. Eastern Europe Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

20. Russia Oncology Biosimilars Market

  • 20.1. Russia Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

21. North America Oncology Biosimilars Market

  • 21.1. North America Oncology Biosimilars Market Overview
  • 21.2. North America Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

22. USA Oncology Biosimilars Market

  • 22.1. USA Oncology Biosimilars Market Overview
  • 22.2. USA Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

23. South America Oncology Biosimilars Market

  • 23.1. South America Oncology Biosimilars Market Overview
  • 23.2. South America Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

24. Brazil Oncology Biosimilars Market

  • 24.1. Brazil Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

25. Middle East Oncology Biosimilars Market

  • 25.1. Middle East Oncology Biosimilars Market Overview
  • 25.2. Middle East Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

26. Africa Oncology Biosimilars Market

  • 26.1. Africa Oncology Biosimilars Market Overview
  • 26.2. Africa Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

27. Oncology Biosimilars Market Competitive Landscape And Company Profiles

  • 27.1. Oncology Biosimilars Market Competitive Landscape
  • 27.2. Oncology Biosimilars Market Company Profiles
    • 27.2.1. Biocoin
      • 27.2.1.1. Overview
      • 27.2.1.2. Products and Services
      • 27.2.1.3. Strategy
      • 27.2.1.4. Financial Performance
    • 27.2.2. Celltrion Inc.
      • 27.2.2.1. Overview
      • 27.2.2.2. Products and Services
      • 27.2.2.3. Strategy
      • 27.2.2.4. Financial Performance
    • 27.2.3. Dr. Reddy's Laboratories Ltd.
      • 27.2.3.1. Overview
      • 27.2.3.2. Products and Services
      • 27.2.3.3. Strategy
      • 27.2.3.4. Financial Performance
    • 27.2.4. Intas Pharmaceuticals Ltd.
      • 27.2.4.1. Overview
      • 27.2.4.2. Products and Services
      • 27.2.4.3. Strategy
      • 27.2.4.4. Financial Performance
    • 27.2.5. STADA Arzneimittel AG
      • 27.2.5.1. Overview
      • 27.2.5.2. Products and Services
      • 27.2.5.3. Strategy
      • 27.2.5.4. Financial Performance

28. Oncology Biosimilars Pipeline Analysis

29. Key Mergers And Acquisitions In The Oncology Biosimilars Market

30. Oncology Biosimilars Market Future Outlook and Potential Analysis

31. Appendix

  • 31.1. Abbreviations
  • 31.2. Currencies
  • 31.3. Historic And Forecast Inflation Rates
  • 31.4. Research Inquiries
  • 31.5. The Business Research Company
  • 31.6. Copyright And Disclaimer
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!